NCT06349642 Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
| NCT ID | NCT06349642 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Early Stage Triple-Negative Breast Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 324 participants |
| Start Date | 2024-04-24 |
| Primary Completion | 2027-05 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
Eligibility Criteria
Inclusion Criteria: Subjects must meet one of the following criteria: * Subjects suspected of or diagnosed with the following Stage IV/metastatic or recurrent malignancies: * Lung: Non-small Cell Lung Cancer (NSCLC) * Skin: Cutaneous Malignancy, excluding Uveal Melanoma * Esophageal Cancer * Cervical Cancer * Endometrial Cancer * Colon Cancer: Mismatch repair deficient (dMMR) CRC only * All solid tumors with high tumor mutation burden (TMB) * All solid tumors that are microsatellite instability high (MSI-H) * All mismatch repair deficient (dMMR) solid tumors * Liver Cancer * Any solid tumor with measurable disease that is eligible for pure ICI therapy or that the clinician plans to treat with immune checkpoint inhibitor (ICI) therapy. NOTE: This can be in the setting of a trial, compassionate use, or the use of appropriate laboratory developed tests (LDTs) that, per clinician, render the patient eligible for ICI therapy, either frontline or a later line. OR * Subjects suspected of or d